Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
1.070
+0.050 (4.90%)
At close: Dec 4, 2025, 4:00 PM EST
1.070
0.00 (0.00%)
After-hours: Dec 4, 2025, 4:59 PM EST
Jaguar Health Employees
Jaguar Health had 49 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
49
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$240,510
Profits / Employee
-$822,306
Market Cap
4.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 49 | 0 | - |
| Dec 31, 2023 | 49 | -11 | -18.33% |
| Dec 31, 2022 | 60 | 8 | 15.38% |
| Dec 31, 2021 | 52 | 18 | 52.94% |
| Dec 31, 2020 | 34 | 5 | 17.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
JAGX News
- 2 days ago - Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study - Accesswire
- 10 days ago - Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones - Accesswire
- 14 days ago - In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial - Accesswire
- 17 days ago - Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 17 days ago - Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - Accesswire
- 20 days ago - Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Accesswire
- 21 days ago - Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting - Accesswire
- 4 weeks ago - REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting - Accesswire